PALI

Palisade Bio, Inc. [PALI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PALI Stock Summary

Top 10 Correlated ETFs

PALI


Top 10 Correlated Stocks

PALI


In the News

08:35 29 Mar 2024 PALI

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.

02:01 29 Mar 2024 PALI

Why Is Palisade Bio (PALI) Stock Up 100% Today?

Biopharmaceutical company Palisade Bio (NASDAQ: PALI ) is seeing its market value skyrocket off multiple encouraging catalysts today. While PALI stock still remains an extremely risky proposition, investors are being buoyed by some key developments.

10:28 29 Mar 2024 PALI

Why Is Palisade Bio (PALI) Stock Down 46% Today?

Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio is selling 2,339,398 shares of PALI stock through a registered direct offering.

09:01 29 Mar 2024 PALI

Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up

Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.

10:11 29 Mar 2024 PALI

Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies

Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said the license gives it exclusive worldwide rights to develop, make and commercialize Giiant's proprietary targeted prodrug platform which specializes in therapies for the IBS market.

08:45 29 Mar 2024 PALI

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET

11:08 29 Mar 2024 PALI

Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Palisade Bio, Inc. (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

03:14 29 Mar 2024 PALI

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

08:06 29 Mar 2024 PALI

Why Is Palisade Bio (PALI) Stock Up 36% Today?

Palisade Bio (NASDAQ: PALI ) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst. Maxim Group is behind today's upgrade for PALI stock.

01:46 29 Mar 2024 PALI

What Makes Palisade Bio, Inc. (PALI) a New Buy Stock

Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PALI Financial details

Company Rating
Sell
Market Cap
4.54M
Income
-11.82M
Revenue
250K
Book val./share
1.92
Cash/share
2.08
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-0.34
Forward P/E
-0.51
PEG
0.04
P/S
20.03
P/B
0.28
P/C
0.19
P/FCF
-0.43
Quick Ratio
5.83
Current Ratio
6.14
Debt / Equity
0.04
LT Debt / Equity
0.01
-
-
EPS (TTM)
-4.57
EPS next Y
-0.79
EPS next Q
-0.32
EPS this Y
-90.03%
EPS next Y
-82.71%
EPS next 5Y
-78.45%
EPS last 5Y
-46.28%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-7.55%
-
-
-
-
SMA20
-7.32%
SMA50
-28.3%
SMA100
-33.33%
Inst Own
862.34%
Inst Trans
8.66%
ROA
-69%
ROE
-84%
ROC
-0.95%
Gross Margin
100%
Oper. Margin
-5506%
Profit Margin
-4728%
Payout
-
Shs Outstand
12.13M
Shs Float
7.33M
-
-
-
-
Target Price
1.5
52W Range
0.36-3.65
52W High
-
52W Low
-
RSI
49.52
Rel Volume
0.05
Avg Volume
2.81M
Volume
131.34K
Perf Week
7.86%
Perf Month
-11.11%
Perf Quarter
-30.11%
Perf Half Y
-26.11%
-
-
-
-
Beta
1.575
-
-
Volatility
0.01%, 0.02%
Prev Close
0.96%
Price
0.3991
Change
5.03%

PALI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
17.152.10.2400
Net income per share
-324.91-1.14K-190.5-145.87-14.54
Operating cash flow per share
-507.52-990.57-85.93-79.02-15.18
Free cash flow per share
-507.63-990.57-86.04-79.02-15.19
Cash per share
381.81698.313.1456.1414.07
Book value per share
399.13699.82-299.2139.3914.18
Tangible book value per share
348.75608.49-299.2139.3914.18
Share holders equity per share
399.13699.82-299.2139.3914.18
Interest debt per share
0.5125.9229.8413.890.47
Market cap
28.19M2.18M14.65M12.15M4.58M
Enterprise value
22.4M-2.76M15.36M1.86M-7.4M
P/E ratio
-5.72-0.26-1.39-0.45-0.36
Price to sales ratio
108.43141.321.08K00
POCF ratio
-3.66-0.3-3.07-0.82-0.34
PFCF ratio
-3.66-0.3-3.07-0.82-0.34
P/B Ratio
4.660.42-0.881.650.37
PTB ratio
4.660.42-0.881.650.37
EV to sales
86.17-179.21.14K00
Enterprise value over EBITDA
-4.740.33-1.52-0.040.49
EV to operating cash flow
-2.910.38-3.22-0.130.55
EV to free cash flow
-2.910.38-3.22-0.130.55
Earnings yield
-0.17-3.84-0.72-2.24-2.8
Free cash flow yield
-0.27-3.34-0.33-1.22-2.92
Debt to equity
00.04-0.090.030.03
Debt to assets
00.030.470.020.03
Net debt to EBITDA
1.220.58-0.070.230.79
Current ratio
6.194.610.114.964.89
Interest coverage
-1.07K-967.68-39.56-17.45-1.21K
Income quality
1.560.870.460.560.94
Dividend Yield
0000.010
Payout ratio
00000
Sales general and administrative to revenue
17.54472.39458.4300
Research and developement to revenue
15.23263.83229.2200
Intangibles to total assets
0.10.1000
Capex to operating cash flow
00000
Capex to revenue
-0.010-0.4400
Capex to depreciation
-0.010-20-3.33
Stock based compensation to revenue
2.44215.99148.9600
Graham number
1.71K4.24K1.13K359.5768.1
ROIC
-2.29-1.640.64-5.59-1.07
Return on tangible assets
-0.71-1.41-3.5-2.18-0.81
Graham Net
291.66501.42-359.7528.8110.74
Working capital
5.46M4.42M-7.19M9.88M11.72M
Tangible asset value
5.29M4.46M-16.6M7.37M12.48M
Net current asset value
4.87M4.19M-18.73M7.23M11.45M
Invested capital
00.04-0.090.030.03
Average receivables
364.79K189.53K40.03K104.5K794K
Average payables
853.81K828.49K2.19M2.54M1.67M
Average inventory
00-1.11M-1.19M-794K
Days sales outstanding
502.57499.441.59K00
Days payables outstanding
008.89K3.3K4K
Days of inventory on hand
00-5.57K-325.89-3.14K
Receivables turnover
0.730.730.2300
Payables turnover
000.040.110.09
Inventory turnover
00-0.07-1.12-0.12
ROE
-0.81-1.630.64-3.7-1.03
Capex per share
-0.110-0.110-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0600
Net income per share
-3.66-3.05-0.5-0.53-0.49
Operating cash flow per share
-3.12-3.76-0.82-0.34-0.36
Free cash flow per share
-3.12-3.77-0.82-0.34-0.36
Cash per share
14.3614.073.082.562.08
Book value per share
12.7614.183.192.461.92
Tangible book value per share
12.7614.183.192.461.92
Share holders equity per share
12.7614.183.192.461.92
Interest debt per share
0.710.460.110.110.07
Market cap
4.87M4.58M15.19M10.91M4.27M
Enterprise value
-8.42M-7.4M2.18M-4.82M-10.54M
P/E ratio
-0.34-0.43-1.77-0.8-0.3
Price to sales ratio
0060.7600
POCF ratio
-1.6-1.38-4.31-4.96-1.61
PFCF ratio
-1.6-1.38-4.31-4.95-1.61
P/B Ratio
0.390.371.110.690.3
PTB ratio
0.390.371.110.690.3
EV to sales
008.7400
Enterprise value over EBITDA
2.131.98-0.931.422.79
EV to operating cash flow
2.772.24-0.622.193.96
EV to free cash flow
2.772.23-0.622.193.96
Earnings yield
-0.73-0.59-0.14-0.31-0.84
Free cash flow yield
-0.62-0.72-0.23-0.2-0.62
Debt to equity
0.060.030.020.040.04
Debt to assets
0.040.030.020.040.03
Net debt to EBITDA
3.363.25.564.643.92
Current ratio
4.314.8910.887.466.14
Interest coverage
-1.1K-1.28K-13.38-1.2K472.25
Income quality
0.760.891.510.650.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
006.1500
Research and developement to revenue
004.9600
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-50-20
Stock based compensation to revenue
000.3700
Graham number
32.4131.175.985.414.6
ROIC
-0.29-0.21-0.16-0.23-0.25
Return on tangible assets
-0.22-0.17-0.14-0.19-0.21
Graham Net
10.4310.742.782.171.68
Working capital
11.65M11.72M12.99M15.08M13.62M
Tangible asset value
12.43M12.48M13.75M15.8M14.08M
Net current asset value
11.32M11.45M12.79M14.92M13.28M
Invested capital
0.060.030.020.040.04
Average receivables
20K729K883K181.5K85K
Average payables
2.01M2.02M1.3M1.04M1.3M
Average inventory
-10K-719K-758K-56.5K-85K
Days sales outstanding
00118.0800
Days payables outstanding
4.32K6.33K2.7K4.3K117.63K
Days of inventory on hand
0-4.98K-270-116.67-12.15K
Receivables turnover
000.7600
Payables turnover
0.020.010.030.020
Inventory turnover
0-0.02-0.33-0.77-0.01
ROE
-0.29-0.21-0.16-0.21-0.26
Capex per share
0-0.01000

PALI Frequently Asked Questions

What is Palisade Bio, Inc. stock symbol ?

Palisade Bio, Inc. is a US stock , located in Carlsbad of Ca and trading under the symbol PALI

Is Palisade Bio, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $1.5. The lowest prediction is $1.5 and the highest is $1.5

What is PALI stock prediction ?

What is Palisade Bio, Inc. stock quote today ?

Palisade Bio, Inc. stock price is $0.3991 today.

Is Palisade Bio, Inc. stock public?

Yes, Palisade Bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap